00:00[Review] The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review -
Jamie Hartmann-Boyce, Patrick Highton, Karen Rees, Igho Onakpoya, Jana Suklan, Ffion Curtis, Lauren O'Mahoney, Elizabeth Morris, Laura Kudlek, Jessica Morgan, Rosie Lynch, Sanjana Marpadga, Samuel Seidu, Kamlesh Khunti
Lancet Diab Endocrinol
The COVID-19 pandemic triggered disruptions to health care and lifestyles that could conceivably impact diabetes management. We set out to identify the impact of disruptions caused by COVID-19 on clinical outcomes in people with diabetes. We performed a systematic review of the available (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00[Articles] Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants -
David J A Jenkins, Walter C Willett, Salim Yusuf, Frank B Hu, Andrea J Glenn, Simin Liu, Andrew Mente, Victoria Miller, Shrikant I Bangdiwala, Hertzel C Gerstein, Sabina Sieri, Pietro Ferrari, Alpa V Patel, Marjorie L McCullough, Loïc Le Marchand, Neal D Freedman, Erikka Loftfield, Rashmi Sinha, Xiao-Ou Shu, Mathilde Touvier, Norie Sawada, Shoichiro Tsugane, Piet A van den Brandt, Kerem Shuval, Tauseef Ahmad Khan, Melanie Paquette, Sandhya Sahye-Pudaruth, Darshna Patel, Teenie Fei Yi Siu, Korbua Srichaikul, Cyril W C Kendall, John L Sievenpiper, Clinical Nutrition & Risk Factor (…)
Lancet Diab Endocrinol
Dietary recommendations to reduce GI and GL could have effects on health outcomes that are similar to outcomes of recommendations to increase intake of fibre and whole grain. (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00
Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 2023; 11: 42–57—In this Review, some values in table 3 should have read 3·9. This correction has been made to the online (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00
Growing up in Egypt, back in the early 1970s, Rafik Jacob was struck by the challenges faced by families who had children with intellectual and developmental disabilities. “There were not a lot of resources around. Parents had to figure everything out for themselves. The whole family was (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00
Recently, GLP-1 receptor agonists, which were originally developed for the treatment of diabetes, have attracted much attention because of their weight loss effects in people with obesity. In Japan, GLP-1 receptor agonists were approved for the treatment of diabetes in January, 2010, and in (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00
There is debate over the nature of the carbohydrate-containing foods that should be recommended to reduce the risk of type 2 diabetes and related conditions. In particular, it is not well established whether glycaemic index (GI) is a relevant dietary factor for the prevention of chronic (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
00:00
The burden of non-communicable diseases (NCDs) cannot be understated. Chronic diseases, including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are responsible for 41 million deaths, almost three-quarters of all deaths globally. Even more alarming is that 17 (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))